Navigation Links
Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System

New Device Significantly Simplifies the Treatment of Abdominal Aortic Aneurysms

IRVINE, Calif., June 1 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX) today announced the full commercial launch of the InutiTrak(TM) Express Delivery System for the endovascular treatment of large neck abdominal aortic aneurysms (AAA). The IntuiTrak family of devices features low profile, minimally invasive endovascular delivery systems that enhance vascular accessibility and maneuverability while simplifying the deployment of the Company's Powerlink stent graft products. As the newest addition to the IntuiTrak platform, IntuiTrak Express incorporates novel design and deployment features that enable the delivery of the Powerlink XL stent graft through the IntuiTrak 19Fr introducer sheath. This is the lowest profile delivery system currently available in the US for the endovascular repair of AAA in patients with aortic necks up to 32mm in diameter.

John McDermott, President and CEO of Endologix, said, "IntuiTrak Express expands our portfolio into a comprehensive suite of products that address a broad range of patient anatomies and physician preferences. Most importantly, it allows physicians to easily deliver and deploy our Powerlink XL stent graft through a single 19Fr introducer sheath, which has demonstrated the potential to reduce procedure times while minimizing blood loss and vessel trauma. We believe this will allow us to gain a greater share of physicians' AAA procedures based upon the ease of use and strong clinical outcomes achieved in patients with large aortic necks and other AAA anatomies. Early physician feedback on IntuiTrak Express was very positive during its limited release, so we accelerated the full commercial launch ahead of our original guidance to launch in the third quarter of this year."

The IntuiTrak Express Delivery System will be featured from June 11-14, 2009 at the Annual Meeting of the Society for Vascular Surgery (SVS) in Denver, Colorado. The Company's complete product portfolio will also be on display at the SVS meeting in the Company's booth #625.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at

Except for historical information contained herein, this news release contains forward-looking statements, specifically with respect to the full commercialization of the IntuiTrak Express Delivery System for the Powerlink XL, accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the success of sales efforts for the Powerlink System and related new products, product research and development efforts, and other economic, business, competitive and regulatory factors. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

    COMPANY CONTACT:                      INVESTOR CONTACTS:
    ----------------                      ------------------
    Endologix, Inc.                       The Ruth Group
    John McDermott, CEO                   Nick Laudico (646) 536-7030
    (949) 595-7200                        Zack Kubow (646) 536-7020

SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
(Date:11/26/2015)... Bangalore, Karnataka (PRWEB) , ... ... ... an innovative online platform for mental health and wellness consultation, has collaborated ... self-empowerment, to holistically address their reader’s queries on topics on mental and ...
(Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
(Date:11/25/2015)... Neb. (PRWEB) , ... November 25, 2015 , ... ... staffing companies, has been recognized once again for its stellar workplace culture with ... to Work.” , Medical Solutions’ Cincinnati office was named a finalist ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
Breaking Medicine Technology: